ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

スルファサラジン

Sulfasalazine

HCID 5339
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
599-79-1
標準SMILES
O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
InChIKey
NCEXYHBECQHGNR-UHFFFAOYSA-N
分子式
C18H14N4O5S
平均分子量
398.4 g/mol
単同位体質量
398.06849055

概要

Sulfasalazine (salicylazosulfapyridine) can cause cancer according to The National Toxicology Program. It can cause male reproductive toxicity according to state or federal government labeling requirements.

名称と識別子

優先名称
Sulfasalazine
IUPAC
2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid
現地名
スルファサラジン
英語名
Sulfasalazine
分子式
C18H14N4O5S
分子量
398.39

名称と別名

sulfasalazine599-79-1SalicylazosulfapyridineSulphasalazineAzulfidineSalazosulfapyridineSalazopyrinBenzosulfaSulcolonSalazopyridinAsulfidineAzopyrine
名称をさらに表示
スルファサラジン2-ヒドロキシ-5-[[4-[[(ピリジン-2-イル)アミノ]スルホニル]フェニル]アゾ]安息香酸5-[[p-(2-ピリジルスルファモイル)フェニル]アゾ]サリチル酸アザルフィジンENアゾピリンサラゾピリンアズルフィジンロラスルエミナピリン5-[4-[(2-ピリジニル)アミノスルホニル]フェニル]アゾサリチル酸サリチルアゾスルファピリジンスラマ4'-[(2-ピリジル)スルファモイル]-4-ヒドロキシアゾベンゼン-3-カルボン酸ソアレジンサフィルジンEN5-[4-[(2-ピリジル)スルファモイル]フェニルアゾ]サリチル酸スルコロンラノフェンサリスルフサラゾスルファピリジンsaspsulfasalazinSSZs.a.s.-500si-88
AccucolAzopyrinSalisulfSalazopiridazinReupirinw-t Sasp oralColo-PleonSalazosulfapyridin

データベース識別子

CAS
599-79-1
PubChem CID
5339
DTXSID
DTXSID0021256
ChEMBL
CHEMBL100848、CHEMBL242373
ChEBI
CHEBI:9334
UNII
3XC8GUZ6CB
Nikkaji
J2.073G

物性

構造計算による物性

XLogP
-0.7
極性表面積
150 Ų
水素結合供与体数
3
水素結合受容体数
9
回転可能結合数
6
重原子数
28
形式電荷
0
複雑度
657

実験および物理化学的性質

Drugs · 4 件

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Analgesics and anti-inflammatories

Pharmaceuticals -> Listed in ZINC15

LogP-0.13
SolubilityPractically insoluble in water
Dissociation Constants · 2 件

2.65

0.6

Collision Cross Section · 4 件

203.9 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID0021256]

199.36 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

200.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

199.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

融点
260 · 260-265 °C (dec.)(lit.)
沸点
689.3 · 689.3±65.0 °C(Predicted)
比重(密度)
1.3742 · 1.3742 (rough estimate)
屈折率
1.6 · 1.6000 (estimate)
貯蔵温度
Keep in dark place,Sealed in dry,Room Temperature
溶解性
4 OH · NH4OH 1 M: 50mg/mL、透明、赤
酸解離定数(Pka)
0.6 · pKa 0.6(H2O t = 20 I < 0.001) (Uncertain);2.4(H2O t = 20 I < 0.001) (Uncertain);9.7(H2O t = 20 I < 0.001) (Uncertain);11.8(H2O t = 20 I < 0.001) (Uncertain)
外見
粉
色
オレンジ
水溶解度
0.1 g/100 · <0.1 g/100 mL で 25 ºC
Merck
14 · 14,8942
BRN
356241 · 356241
BCS Class
2 · 2,4
安定性
-20 °C · -20°C の DMSO 溶液で最大 1 か月間保存できます。
主な用途
法医学と毒物学医薬品(低分子化合物)
InChI
1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
InChIKey
NCEXYHBECQHGNR-QZQOTICOSA-N
SMILES
OC(=O)c1cc(ccc1O)\N=N\c2ccc(cc2)S(=O)(=O)Nc3ccccn3
CAS データベース
599 · 599-79-1(CAS DataBase Reference)
EPAの化学物質情報
Salicylazosulfapyridine (599-79-1)

化学的性質

化学的特性Brownish-Yellow Crystals

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Sulfasalazine

46.6

197.2

Maintenance therapy dosage for adults is 2 g daily.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 2000 mg/day, Lowest Therapeutic Dose (LTD): 25.0 mg/kg-day, and Screening Dose: 0.008 mg/kg-day.

10-Feb-21

安全データ

F
8
wgk
2
rtecs
VO6250000
ridadr
3077
毒性
LD50 oral in rabbit: > 7500mg/kg
hs_code
2933399090
risk_code
42/43
化審法
(9)-483
hazard_code
Xn
safety_code
22-29/56-45
Hazard Classifications
Aquatic Chronic 2Carc. 2Repr. 2Resp. Sens. 1Skin Sens. 1
ストレージクラス
11 - Combustible Solids
有毒物質データの
599-79-1(Hazardous Substances Data)

化学と産業

薬理情報

ATC CodeA07EC01
Protein BindingSulfasalazine is highly bound to albumin (>99.3%) while sulfapyridine is only about 70% bound to albumin. Acetylsulfapyridine, the principal metabolite of sulfapyridine, is approximately 90% bound to plasma proteins.
Pharmacodynamics · 1 件

The mode of action of sulfasalazine or its metabolites, 5-aminosalicylic acid and sulfapyridine, is still under investigation but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and <i>in vitro</i> models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver, and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of sulfasalazine, sulfapyridine, and 5-aminosalicylic acid have indicated that the major therapeutic action may reside in the 5-aminosalicylic acid moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown.

Mechanism of Action · 1 件

Although the exact mechanism of action of sulfasalazine is not fully understood, it is thought to be mediated through the inhibition of various inflammatory molecules. Research have found that sulfasalazine and its metabolites, mesalazine and sulfapyridine, can inhibit leukotrienes and prostaglandins by blocking the cyclo-oxygenase and lipoxygenase pathway. Specific enzymes that were investigated include phospholipase A2, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX2), and arachidonate 5-lipoxygenase. Inhibitory activities on other non-arachidonic acid derivatives have also been observed, including PPAR gamma, NF-Kb, and IkappaB kinases alpha and beta.

Biological Half-Life · 1 件

The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.In fast acetylators, the mean plasma half-life of sulfapyridine is 10.4 hours while in slow acetylators, it is 14.8 hours.Due to low plasma levels produced by 5-aminosalicylic acid after oral administration, reliable estimates of plasma half-life are not possible.

Metabolism/Metabolites · 1 件

In the intestine, sulfasalazine is metabolized by intestinal bacteria to sulfapyridine and 5-aminosalicylic acid. Of the two species, sulfapyridine is relatively well absorbed from the intestine and highly metabolized, while 5-aminosalicylic acid is much less well absorbed.Approximately 15% of a dose of sulfasalazine is absorbed as the parent drug and is metabolized to some extent in the liver to the same two species.Sulfapyridine can also be metabolized to 5-hydroxysulfapyridine and N-acetyl-5-hydroxy sulfapyridine. 5-aminosalicylic acid is primarily metabolized in both the liver and intestine to N-acetyl-5 aminosalicylic acid via a non-acetylation phenotype-dependent route.

Absorption, Distribution and Excretion · 4 件

Following oral administration of 1 g of sulfasalazine to 9 healthy males, less than 15% of a dose of sulfasalazine is absorbed as the parent drug. Detectable serum concentrations of sulfasalazine have been found in healthy subjects within 90 minutes after ingestion. Maximum concentrations of sulfasalazine occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 μg/mL) occurring at 6 hours.

Absorbed sulfapyridine and 5-aminosalicylic acid and their metabolites are primarily eliminated in the urine either as free metabolites or as glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-aminosalicylic acid and acetyl-5-aminosalicylic acid in the feces.

Following intravenous injection, the calculated volume of distribution for sulfasalazine was 7.5 ± 1.6 L.

The calculated clearance of sulfasalazine following intravenous administration was 1 L/hr. Renal clearance was estimated to account for 37% of total clearance.

応用分野 · 6 件

解説[同義異語]サラゾスルファピリジン森北出版「化学辞典(第2版)

用途抗炎症剤です。好中球接着抑 制作用や白血球浸潤抑制作用により抗炎症作 用を示します。

用途抗炎症剤です。好中球接着抑 制作用や白血球浸潤抑制作用を示します。

説明Sulfasalazine (brand name Azulfidine in the U.S., Salazopyrin and Sulazine in Europe and Hong Kong) was developed in the 1950s specifically to treat rheumatoid arthritis. It was believed at the time that bacterial infections were the cause of rheumatoid arthritis. Sulfasalazine is a sulfa drug, (a derivative of mesalazine) and is formed by combining sulfa pyridine and salicylate with an azo bond. It may be abbreviated SSZ.

使用Sulfasalazine is an anti-inflammatory (gastrointestinal). Sulfasalazine has been used in granulomatous colitis.

一般的な説明Odorless yellow or brownish-yellow to orange powder. Tasteless.

上流・下流製品情報

上流原料

ベンゼンスルホニルクロリド酢酸2-アミノピリジンスルファピリジンアセトアニリド5-アミノサリチル酸4-Nitroso-N-2-pyridinylbenzenesulfonamide2-ヒドロキシ安息香酸4-アセトアミドベンゼンスルホニルクロリド水酸化ナトリウム

補足説明

定義ChEBI: An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

関連反応

4 件
反応記録を作成
HRID 1750338 の反応式
HRID 1750338反応物として
HRID 2202207 の反応式
HRID 2202207反応物として
HRID 2205960 の反応式
HRID 2205960反応物として
HRID 2272552 の反応式
HRID 2272552反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート